Key Developments in ALL Immunotherapy - prIME Oncology
Expert Review
Expert Review

Key Developments in ALL Immunotherapy

Digging to New Depths

Not a member of My prIME? Join now for instant access.

Stay current on immunotherapy options for the treatment of acute lymphoblastic leukemia (ALL). Tune in for an expert discussion focused on immunotherapy in relapsed/refractory ALL, how minimal residual disease (MRD) can influence treatment decisions, and a discussion of common toxicities associated with novel immunotherapies in ALL.

Don’t miss the downloadable clinical companion tool designed to help you identify and manage adverse events associated with immunotherapies. Click here to download the tool.

Interactive Presentation

Interactive Presentation



1.0 AMA PRA Category 1 Credit™

Release Date

Release Date

Mar 15, 2019

Expiration Date

Mar 15, 2020

  • Anjali Advani, MDCleveland Clinic
    Cleveland, Ohio, United States
  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Immunotherapy in relapsed/refractory ALL
  • Minimal residual disease in ALL treatment
  • Adverse events associated with immunotherapy

The activity is designed to address challenges experienced by hematologists, oncologists, and other healthcare professionals who manage acute lymphoblastic leukemia.

After successful completion of this educational activity, participants should be able to:

  • Develop optimal treatment strategies using novel immunotherapy treatment options for relapsed/refractory ALL
  • Discuss the evidence and best practices for use of MRD assessment to personalize treatment for ALL
  • Implement strategies to detect and manage the adverse events associated with immunotherapy options for ALL

This educational activity is supported by a grant from Amgen.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 1.0 hours

To contact Postgraduate Institute for Medicine please visit

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Advani has disclosed that she has received consulting fees from GlycoMimetics, Kite Pharma, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Jabbour has disclosed that he has performed contracted research for AbbVie, Amgen, Bristol-Myers Squibb, Novartis Oncology, Pfizer, Spectrum, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed the following:

  • Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
  • Briana Betz, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.